Tafenoquine - GlaxoSmithKline/60 Degrees Pharmaceuticals

Drug Profile

Tafenoquine - GlaxoSmithKline/60 Degrees Pharmaceuticals

Alternative Names: 60P 003; Etaquine; SB-252263; SB-252263-AAB; SB-252263-AX; Tafenoquine maleate; Tafenoquine succinate; WR 238605; WR 238605 succinate

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer GlaxoSmithKline; Medicines for Malaria Venture
  • Class Aminoquinolines; Antimalarials; Antiprotozoals; Small molecules
  • Mechanism of Action Electron transport complex III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Malaria
  • Discontinued Babesiosis; Pneumocystis pneumonia

Most Recent Events

  • 12 Jul 2018 The US FDA's Antimicrobial Drugs Advisory Committee adopts a positive opinion for the use of single-dose tafenoquine for Malaria
  • 08 Apr 2018 Phase-III clinical trials in Malaria (Combination therapy) in Indonesia (PO) (NCT02802501)
  • 08 Feb 2018 Tafenoquine - GlaxoSmithKline/60 Degrees Pharmaceuticals receives priority review designation for Malaria (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top